Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

项目摘要 虽然一些创新和创造性的免疫肿瘤学(IO)策略已经显示出令人振奋的结果，但 它们的临床应用的显著扩展将需要合作努力来阐明耐药机制， 发现新的免疫靶点，识别预测性生物标记物，评估联合疗法，并开发 采取预防性的方法。利用多学科团队的方法，我们将支持免疫肿瘤学 翻译网络(IOTN)资助的组件，以发现新的免疫靶点并评估新的免疫- 以消除成人已确诊癌症或预防癌症为基础的治疗和组合方法 防患于未然。我们的DMRC战略是作为每一步的管理和分析中心 IOTN的翻译研究的重点是减少获得分析专业知识的障碍，改进 提高物联网调查人员的工作效率，保持高标准的数据收集和管理、设计和 执行严格的分析策略，并培养一个协作和支持的研究社区。 已经组建了一支经验丰富的多学科团队，以实现四个具体目标：第一，我们将提供 以NRG肿瘤学为基础的用于协调IOTN活动的集中式管理基础设施 统计与数据协调中心协调450多项癌症转化性研究的经验 涉及数百个参与站点。第二，我们将提供多学科分析专业知识来支持 IOTN协作研究，利用RPCICCSG的五个共享资源：生物统计、生物信息学、 生物医学数据科学，数据库和生物仓库，免疫分析。我们的分析支持将是 配备专业的IT人员，并由经验丰富的IO研究团队提供信息。三是大力发展 创新数据集成方法，增强物联网研究能力，利用备受尊敬的 生物导体项目和RPCI部生物统计和独立研究计划 生物信息学。第四，积极推进物联网，开展跨联合体互动， 我们将利用BioConductor在社区参与方面的十年经验和NRG数据中心的 具有丰富的项目协调专业知识。利用我们由积极的NCI资助的RPCI承诺的资源来支持 拟议的多机构跨学科IO研究不仅具有成本效益，而且在其 依赖研究的可扩展性。综上所述，我们设想我们的DMRC将与IOTN密切合作， 将使我们能够进行高效和创新的翻译研究，以解决严重未满足的问题 与IO相关的临床需求。

Project Summary While several innovative and creative immuno-oncology (IO) strategies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate the resistance mechanism, discover new immune targets, identify predictive biomarkers, evaluate combination therapies, and develop preventive approaches. Utilizing a multi-disciplinary team approach, we will support Immuno-Oncology Translation Network (IOTN)-funded components to discover new immune targets and evaluate novel immune- based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. Our DMRC strategy is to serve as an administrative and analytic hub at every step of the IOTN's translational studies, focusing to reduce the barrier for access to analytic expertise, improve the productivity of IOTN investigators, maintain a high standard for data collection and management, design and perform rigorous analytical strategies, and foster a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue four specific aims: First, we will provide a centralized administration infrastructure to coordinate IOTN activities, building upon the NRG Oncology Statistical and Data Coordinating Center's experience of coordinating over 450 translational cancer studies across hundreds of participating sites. Second, we will provide multidisciplinary analytic expertise to support IOTN collaborative research, leveraging five of RPCI CCSG's shared resources: Biostatistics, Bioinformatics, Biomedical Data Science, Data Bank and BioRepository, and Immune Analysis. Our analytic support will be armed with professional IT staff and informed by an experienced IO researcher team. Third, we will develop innovative data integration methods to enhance IOTN research capacity, capitalizing on the well-respected Bioconductor project and the independent research programs of the RPCI department of Biostatistics and Bioinformatics. Fourth, we will actively promote the IOTN and engage in trans-consortium interactions, where we will leverage Bioconductor's decade-long experience in community engagement and the NRG data center's rich expertise in project coordination. Leveraging our active NCI-funded RPCI-committed resource to support the proposed multi-institutional trans-disciplinary IO research is not only cost-effective, but also flexible in its study-dependent scalability. Taken together, we envision that our DMRC, in close collaboration with the IOTN, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet clinical needs related to IO.